Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 11/20 | 0.33 |
| ▸ | SLC5A1 | P13866 | 4/20 | 0.32 |
| ▸ | TACR2 | P21452 | 1/20 | 0.31 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14954842 | 0.95 | SLC5A2 (0.31) | SLC5A2TACR2 | |
| SCHEMBL10040998 | 0.94 | SLC5A2 (0.39) | SLC5A2SLC5A1TACR2 | |
| SCHEMBL17108895 | 0.94 | SLC5A2 (0.33) | SLC5A2SLC5A1 | |
| SCHEMBL14954781 | 0.94 | SLC5A2 (0.39) | SLC5A2SLC5A1TACR2 | |
| SCHEMBL14954664 | 0.91 | SLC5A2 (0.31) | SLC5A2 | |
| SCHEMBL17108896 | 0.88 | SLC5A2 (0.33) | SLC5A2SLC5A1 | |
| SCHEMBL17108910 | 0.88 | SLC5A2 (0.38) | SLC5A2SLC5A1 | |
| SCHEMBL14958463 | 0.87 | SLC5A2 (0.33) | SLC5A2SLC5A1 | |
| SCHEMBL14954903 | 0.86 | SLC5A2 (0.32) | SLC5A2 | |
| SCHEMBL17115127 | 0.86 | SLC5A2 (0.34) | SLC5A2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2604612-A1 | C-ARYL GLUCOSIDE DERIVATIVES, PREPARATION RPOCESS AND PHARMACEUTICAL USE THEREOF | Shanghai Hengrui Pharmaceutical Co. Ltd. (CN) | 2013-06-19 | — | — | EP | disclosed |
| US-20130130997-A1 | C-ARYL GLUCOSIDE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2013-05-23 | — | — | US | disclosed |
| US-20130130997-A1 | C-ARYL GLUCOSIDE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2013-05-23 | — | — | US | disclosed |
| WO-2012019496-A1 | C-ARYL GLUCOSIDE DERIVATIVES, PREPARATION RPOCESS AND PHARMACEUTICAL USE THEREOF | 上海恒瑞医药有限公司 (CN) | 2012-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130130997-A1 | C-ARYL GLUCOSIDE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | SLC5A1, SLC5A2, UGGT1 | SLC5A2 2/4885SLC5A1 1/4885TACR2 2493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.